Phio Pharmaceuticals Corp. (PHIO): Operating Income
-$9.22M
Year ended 2025-12-31
-$13.47M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$9.22M | n/m | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | -$7.39M | n/m | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | -$10.82M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$11.46M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$13.51M | n/m | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | -$8.79M | n/m | 2022-03-22, From 2020-01-01 |
| 2019-12-31 | -$8.99M | n/m | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | -$7.36M | n/m | 2020-03-26, From 2018-01-01 |
| 2017-12-31 | -$14.06M | n/m | 2019-03-27, From 2017-01-01 |
| 2016-12-31 | -$9.02M | n/m | 2018-03-26, From 2016-01-01 |
| 2015-12-31 | -$10.24M | n/m | 2017-03-30, From 2015-01-01 |
| 2014-12-31 | -$8.83M | n/m | 2016-03-30, From 2014-01-01 |
| 2013-12-31 | -$20.95M | n/m | 2015-03-30, From 2013-01-01 |
| 2012-12-31 | -$12.97M | n/m | 2014-03-28, From 2012-01-01 |
| 2011-12-31 | -$12.77M | n/a | 2013-03-29, From 2011-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | -$9.22M | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $231.0K | n/m |
| BriaCell Therapeutics Corp. (BCTX) | 2025-07-31 | -$27.20M | n/m |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | -$29.70M | n/m |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | -$7.15M | n/m |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | -$25.10M | n/m |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | -$2.61M | n/m |
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | -$4.23M | n/m |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $3.37M | n/m |
Compare PHIO, EMMA, BCTX, ANVS side by side · Screen every company in Pharmaceutical Preparations ↗